Polymorphisms in XPD protein is associated with risk of primary lung cancer

The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk.

polymorphism and risk of lung cancer in a Chinese population

the XPD variant alleles may be associated with an increased frequency of smoking-related p53 mutations in lung tumors, presumably due to reduced DNA repair proficiency.

Findings indicate that the Asp312Asn and Lys751Gln polymorphisms in the XPD locus are associated with the risk of lung Squamous Cell Carcinoma (SCC) but not lung adenocarcinoma or esophageal SCC in this Chinese population.

Cumulative cigarette smoking plays an important role in altering the direction and magnitude of the associations between the XRCC1 and ERCC2 polymorphisms and lung cancer risk.

The Asp312Asn and Lys751Gln polymorphisms in the XPD gene may alter DNA repair capacity. The hypothesis that these 2 XPD polymorphisms are associated with risk of lung cancer was confirmed in a large hospital-based, case-control study among Chinese.

Single Nucleotide Polymorphism in the ERCC2 is associated with lung cancer

identification of polymorphisms in lung carcinoma of never smokers

Larger sample sizes are needed to elucidate the effects of ERCC2 polymorphisms on lung cancer risk in this northeastern Chinese population.

no association between XPD Lys751Gln genotype and clinical outcome of lung cancer was found

The XPD Lys751Glncc variant genotype was associated with higher risk for lung cancer among men and lower risk among women.

Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.

XPD c varian allele associated with a higher rate of lung cancer than XPD wild-type allele.

Study, for the first time, provides suggestive evidence of an effect of XPD p.Arg(156)Arg polymorphism on severe toxicity variability among platinum-treated non-small cell lung cancer patients.

ERCC2 751 polymorphism may be a genetic risk modifier for lung adenocarcinoma in non-smoking females in China.

XPD gene polymorphism is not associated with outcome of platinum-based chemotherapy for advanced non small cell lung cancers.

XPD polymorphism not associated with tumor response to platinum therapy for non-small-cell lung cancer

this meta-analysis suggests that the XPD Asn allele is a low-penetrant risk factor for developing lung cancer.

this meta-analysis suggests that the ERCC2 Lys751Gln polymorphism may contribute to lung cancer susceptibility among Caucasians.

XPD Lys751Gln and Asp312Asn gene polymorphisms are associated with lung cancer.

XPD 312A allele is risk allele for lung cancer.

genetic polymorphisms is not a prognostic predictor of platinum-based chemotherapy outcomes in non-small cell lung cancer

Our findings indicated that neither XPD Lys751Gln nor XRCC1 T-77C could be genetic determinant for prognosis of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy

ERCC2 gene polymorphism is associated with lung cancer.

data suggest that common genetic variations in ERCC1 may influence increased risk of smoking-related lung cancer and one of the causative effectors may locate around or within ERCC2

Meta-analysis suggests that two ERCC2 polymorphisms (Asp312Asn and Lys751Gln) may contribute to lung cancer susceptibility serving as low-penetrance risk factors.

XPD codon 751 polymorphism is not associated with response to chemptherapy in non-small cell lung cancer.

XPD gene polymorphism is not associated with chemotherapy-induced neutropenia non-small-cell lung cancer.

Data show the predictive role of xeroderma pigmentosum group D (XPD) polymorphisms/haplotype on non-small cell lung cancer (NSCLC) prognosis in inoperable advanced NSCLC patients treated with platinum-based chemotherapy.

A three-order interaction among the polymorphic sites of XPD-751, XRCC1-399, and OGG1-326 is associated with lung adenocarcinoma risk.

XPD Asp312Asn polymorphism may function as a predictive biomarker on platinum-based chemotherapy in non-small cell lung cancer. (Meta-analysis)

this meta-analysis suggested ERCC2 Asp312Asn polymorphism may increase the risk of lung cancer among Asians, whereas not among Caucasians

Haplotype ERCC2 rs3916874 polymorphism is associated with lung cancer risk.

meta-analysis suggested that the ERCC1 C118T, ERCC2 Asp312Asn, and Lys751Gln may be useful biomarkers to predict the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer patients

Conducted a comprehensive meta-analysis to assess the correlation between ERCC2 Lys751Gln polymorphism and an increased risk of lung cancer. Our research shows that ERCC2 Lys751Gln polymorphism carries an increased risk of developing lung cancer.

The combined Gln/Gln genotype of XRCC1 and XPD genes was significantly associated with increased risk for lung cancer.

XPD rs13181 may be associated with an increase in the risk of lung cancer among Caucasian populations

Study provides evidence that genetic polymorphisms in XPD-751, XRCC1-194 and XRCC1-399 were all correlated with non-small cell lung cancer occurrence.

we evaluated the association of gene polymorphisms, including the repair genes of XRCC1, ERCC1, ERCC2 (XPD), and TP53, with RFS in patients with non-small cell lung cancer

Polymorphisms in ERCC2/XPD Asp312Asn may be associated with increased DNA adduct levels in the lung, especially among subjects with squamous cell carcinoma.

the combined effects of BAG-1 and XPD polymorphisms on chemotherapy sensitivity and survival in patients with advanced non-small-cell lung cancer, which might be the important predictive markers for platinum-based chemotherapy efficacy.

ERCC1/2 SNP, predict radiation dose-response and potentially guide personalized radiotherapy in non-small cell lung cancer.

The analysis results showed that the following polymorphisms were correlated with susceptibility to lung cancer: rs4646903 in CYP1A1 (P < 0.001), rs1048943 in CYP1A1 (P < 0.001), rs1695 in GSTP1 (P < 0.05), rs13181 in ERCC2 (P < 0.001), and rs25487 in XRCC1 (P < 0.05); no such correlation existed in rs861539 in XRCC3 (P > 0.05).

XPD 312 single nucleotide polymorphism is associated with Non-Small-Cell lung cancer.

a combination of ERCC1 and ERCC2 polymorphisms may predict overall survival among pemetrexed/platinum treated advanced non-squamous non-small-cell lung cancer patients

Homozygous CC genotype of the polymorphic site of gene XPD A751C is associated with non-small cell lung cancer development. Statistically significant differences in the distribution of polymorphic variants of gene A751C XPD depending on spread of cancer were not received.

XRCC1 and XPD polymorphisms, cooking oil mist, and soot exposure history may be interactively correlated with non-small-cell lung cancer incidence for nonsmoking female patients.

ERCC2 Lys751Gln rs13181 and XRCC2 Arg188His rs3218536 Gene Polymorphisms Contribute to Subsceptibility of Colon, Gastric, HCC, lung And Prostate cancer.

TP53 Arg72Pro and XPD Lys751Gln Gene Polymorphisms and Risk of lung cancer in Bangladeshi Patients.

ERCC2 plays role in lung cancer development in a Chinese population.